AstraZeneca Q3 financial report: China's market revenue of US $1.28 billion increased by 40%!

Recently, British pharmaceutical giant AstraZeneca released its financial report for the third quarter of 2019 Driven by emerging markets and China, AstraZeneca achieved the fifth consecutive quarter of growth During the reporting period, the company's global sales reached US $6.13 billion, up 18% year-on-year (all growth data are calculated at constant exchange rate) Prior to that, sales of the company had been in a low state due to the expiration of original drug patents and the slow progress of new product listing But new treatments for diabetes, asthma and cancer have helped to reverse years of declining sales In the third quarter, the company's new drug sales increased 64% year on year to US $2.71 billion, accounting for 22% of global sales During the reporting period, AstraZeneca achieved strong results in emerging markets including China, with sales reaching US $2.12 billion, a year-on-year growth of 29%, accounting for 35% of global sales, of which sales in China increased by 40% to US $1.28 billion Its total sales in China in the first three quarters were US $3.69 billion, up 37% year on year, which means that AstraZeneca's China business is expected to exceed US $5 billion in annual sales this year AstraZeneca's market performance in the United States and Japan is also very impressive, with sales in the United States and Japan reaching US $2.03 billion and US $657 million respectively, up 17% and 27% year on year In the financial report conference call, the company's executives pointed out that even after the "4 + 7" volume procurement nationwide expanded or expanded to more varieties in 2020, the company's China business is expected to maintain a growth rate of "more than 10%" Although rosuvastatin of AstraZeneca was not selected in the new round of belt purchase, gefitinib of AstraZeneca successfully won the bid of "4 + 7" after reducing its price by 75% last year, and continued to win the bid in this round of belt purchase at the same price "Sales of both products are likely to decline, but I don't think they will exit the market," said Leon Wang, President of AstraZeneca China However, AstraZeneca's third generation lung cancer targeting drug, osimertinib, was included in the national medical insurance catalog in 2017 for the second-line treatment of non-small cell lung cancer (NSCLC) Since then, the market penetration of the drug in China has been increasing, which to some extent offset the adverse impact of volume purchase on the company In the first three quarters of 2019, the sales volume of AstraZeneca oncology drugs reached US $1.02 billion, a year-on-year increase of 67% Thereinto, Teresa was approved in China in September this year for the first-line treatment of EGFR positive NSCLC patients Other products with strong performance include Belinda, which treats heart attacks and strokes, which entered the national health insurance catalog in 2017 and has been selling well In addition, farxiga and lynparza, the SGLT2 inhibitors, have not yet entered the national health insurance catalogue, but they still have a satisfactory market performance Olapani was approved for maintenance treatment of platinum sensitive recurrent ovarian cancer in China in August 2018, and was strongly launched in China During the reporting period, the drug boosted sales in emerging markets by 227% to US $101 million In August 2019, after the national medical insurance catalog was adjusted, kombiglyze, a type II diabetes treatment drug, entered the regular catalog, and the respiratory system drug symbiort (budesonide / formoterol) was no longer a drug limited to second-line drugs Wang Lei said in response that last year, 10 products of the company were included in the national essential drug catalog, including: brinta (ticagre), symbiort (xinbicort), Pulmicort (Pulmicort Lingshu) and farxiga (andatang), etc., which will hopefully enter the medical insurance catalog this year Wang also stressed that access to the base drug catalog can ensure the purchase volume of hospitals at all levels, and that this will be particularly important for the future market as the Chinese government uses the policy to promote rational use of drugs In addition, Wang said farxiga, lynparza and roxadustat, a new anemia drug, have entered the price negotiation stage of the health insurance catalog PD-L1 imfinzi will be approved, and phase III test of combination of voritinib and sunitinib will be stopped The company PD-L1 tumor immunotherapy imfinzi (durvalumab), budesonide / glulammonium / breztri aerosphere and bevespi aerosphere, the triple therapy for COPD, will be approved and listed in China in the next few months, and the strong commercial team of AstraZeneca has been in the limelight Please refer to the table below for major R & D Progress of the company's products in China in the future Prospect of AstraZeneca's R & D pipeline in China